{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T23:18:11Z","timestamp":1780960691704,"version":"3.54.1"},"reference-count":69,"publisher":"Oxford University Press (OUP)","issue":"5-6","license":[{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"N\/A"},{"name":"N\/A","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"N\/A"},{"name":"N\/A","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,18]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Combat-related wound infections complicate the recovery of wounded military personnel, contributing to overall morbidity and mortality. Wound infections in combat settings present unique challenges because of the size and depth of the wounds, the need to administer emergency care in the field, and the need for subsequent treatment in military facilities. Given the increase in multidrug-resistant pathogens, a novel, broad-spectrum antibiotic is desired across this continuum of care when the standard of care fails. Omadacycline was FDA-approved in 2018 for treatment of adults with acute bacterial skin and skin structure infections (ABSSSI), as well as community-acquired bacterial pneumonia (CABP). It is a broad-spectrum antibiotic with activity against gram-positive, gram-negative, and atypical bacterial pathogens, including multidrug-resistant species. Omadacycline can overcome commonly reported tetracycline resistance mechanisms, ribosomal protection proteins, and efflux pumps, and is available in once-daily intravenous or oral formulations. In this review, we discuss the potential role of omadacycline, which is included in the Department of Defense Formulary, in the context of combat wound infections.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>A literature review was undertaken for manuscripts published before July 21, 2023. This included a series of publications found via PubMed and a bibliography made publicly available on the Paratek Pharmaceuticals, Inc. website. Publications presenting primary data published in English on omadacycline in relation to ESKAPEE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Escherichia coli, and Enterobacter species) pathogens and Clostridioides difficile, including in vitro, in vivo, and clinical data were included.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 260 identified records, 66 were included for evidence review. Omadacycline has in vitro activity against almost all the ESKAPEE pathogens, apart from P. aeruginosa. Importantly, it has activity against the four most prevalent bacterial pathogens that cause wound infections in the military healthcare system: S. aureus, including methicillin-resistant S. aureus, A. baumannii, K. pneumoniae, and E. coli. In vivo studies in rats have shown that omadacycline is rapidly distributed in most tissues, with the highest tissue-to-blood concentration ratios in bone mineral. The clinical efficacy of omadacycline has been assessed in three separate Phase 3 studies in patients with ABSSSI (OASIS-1 and OASIS-2) and with CABP (OPTIC). Overall, omadacycline has an established safety profile in the treatment of both ABSSSI and CABP.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Omadacycline has broad-spectrum activity, the option to be orally administered and an established safety profile, making it a potentially attractive replacement for moxifloxacin in the military individual first aid kit, especially when accounting for the increasing resistance to fluoroquinolones. Further studies and clinical evaluation are warranted to support broader use of omadacycline to treat combat wound infections in the military healthcare system.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/milmed\/usad417","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T18:43:10Z","timestamp":1699987390000},"page":"e1353-e1361","source":"Crossref","is-referenced-by-count":7,"title":["A Review of\u00a0Omadacycline for\u00a0Potential Utility in\u00a0the Military Health System for\u00a0the Treatment of\u00a0Wound Infections"],"prefix":"10.1093","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7920-5601","authenticated-orcid":false,"given":"Daniel V","family":"Zurawski","sequence":"first","affiliation":[{"name":"Wound Infections Department, Bacterial Diseases Branch, Center for Infectious Diseases Research, Walter Reed Army Institute of Research , Silver Spring, MD 20910,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2351-6320","authenticated-orcid":false,"given":"Alisa W","family":"Serio","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals , King of Prussia, PA 19406,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Black","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics Branch, Center for Infectious Diseases Research, Walter Reed Army Institute of Research , Silver Spring, MD 20910,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Pybus","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics Branch, Center for Infectious Diseases Research, Walter Reed Army Institute of Research , Silver Spring, MD 20910,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5843-5363","authenticated-orcid":false,"given":"Kevin S","family":"Akers","sequence":"additional","affiliation":[{"name":"Combat Wound Care Research Team (CRT4), U.S. Army Institute of Surgical Research , San Antonio, TX 78234,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H","family":"Deck","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals , King of Prussia, PA 19406,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Johnson","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics Branch, Center for Infectious Diseases Research, Walter Reed Army Institute of Research , Silver Spring, MD 20910,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4615-1034","authenticated-orcid":false,"given":"Supaksorn","family":"Chattagul","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics Branch, Center for Infectious Diseases Research, Walter Reed Army Institute of Research , Silver Spring, MD 20910,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9672-4297","authenticated-orcid":false,"given":"Schroeder M","family":"Noble","sequence":"additional","affiliation":[{"name":"Wound Infections Department, Bacterial Diseases Branch, Center for Infectious Diseases Research, Walter Reed Army Institute of Research , Silver Spring, MD 20910,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2324-1662","authenticated-orcid":false,"given":"Malik","family":"Raynor","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics Branch, Center for Infectious Diseases Research, Walter Reed Army Institute of Research , Silver Spring, MD 20910,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte A","family":"Lanteri","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics Branch, Center for Infectious Diseases Research, Walter Reed Army Institute of Research , Silver Spring, MD 20910,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,10,31]]},"reference":[{"issue":"2","key":"2025012315141362200_R1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.diagmicrobio.2018.12.008","article-title":"Microbiology of\u00a0combat-related extremity wounds: trauma infectious disease outcomes study","volume":"94","author":"Mende","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"3","key":"2025012315141362200_R2","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1089\/sur.2017.002","article-title":"Multi-drug-resistant gram-negative infections in\u00a0deployment-related trauma patients","volume":"18","author":"Campbell","year":"2017","journal-title":"Surg Infect (Larchmt)"},{"issue":"1","key":"2025012315141362200_R3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1089\/sur.2017.157","article-title":"Association of\u00a0Enterococcus spp. with severe combat extremity injury, intensive care, and\u00a0polymicrobial wound infection","volume":"19","author":"Heitkamp","year":"2018","journal-title":"Surg Infect (Larchmt)"},{"issue":"1 Suppl","key":"2025012315141362200_R4","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1097\/TA.0b013e318221162e","article-title":"Infection-associated clinical outcomes in\u00a0hospitalized medical evacuees after traumatic injury: trauma infectious disease outcome study","volume":"71","author":"Tribble","year":"2011","journal-title":"J Trauma"},{"issue":"3","key":"2025012315141362200_R5","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1089\/sur.2017.240","article-title":"Early infections complicating the care of\u00a0combat casualties from Iraq and\u00a0Afghanistan","volume":"19","author":"Weintrob","year":"2018","journal-title":"Surg Infect (Larchmt)"},{"issue":"Suppl 2","key":"2025012315141362200_R6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/milmed\/usz027","article-title":"After the battlefield: infectious complications among wounded warriors in\u00a0the trauma infectious disease outcomes study","volume":"184","author":"Tribble","year":"2019","journal-title":"Mil Med"},{"issue":"7","key":"2025012315141362200_R7","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/apm.13119","article-title":"Evaluation of\u00a0Pseudomonas aeruginosa pathogenesis and\u00a0therapeutics in\u00a0military-relevant animal infection models","volume":"130","author":"Bobrov","year":"2022","journal-title":"Apmis"},{"key":"2025012315141362200_R8","article-title":"Medical Platoon","author":"Army Publishing Directorate"},{"key":"2025012315141362200_R9","article-title":"The Medical Company (Role 2)","author":"Army Publishing Directorate"},{"key":"2025012315141362200_R10","article-title":"Theater Hospitalization","author":"Army Publishing Directorate"},{"key":"2025012315141362200_R11","article-title":"Tactical Field Care","author":"Medicine"},{"issue":"2 Suppl 2","key":"2025012315141362200_R12","doi-asserted-by":"publisher","first-page":"S210","DOI":"10.1097\/TA.0b013e318227ac4b","article-title":"Guidelines for\u00a0the prevention of\u00a0infections associated with combat-related injuries: 2011 update: endorsed by the Infectious Diseases Society of\u00a0America and\u00a0the Surgical Infection Society","volume":"71","author":"Hospenthal","year":"2011","journal-title":"J Trauma"},{"issue":"4","key":"2025012315141362200_R13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40719-017-0102-2","article-title":"Infectious complications after battlefield injuries: epidemiology, prevention, and\u00a0treatment","volume":"3","author":"Yun","year":"2017","journal-title":"Current Trauma Reports"},{"issue":"S1","key":"2025012315141362200_R14","doi-asserted-by":"publisher","first-page":"346","DOI":"10.7205\/MILMED-D-16-00040","article-title":"Variation in\u00a0postinjury antibiotic prophylaxis patterns over five years in\u00a0a combat zone","volume":"182","author":"Lloyd","year":"2017","journal-title":"Mil Med"},{"issue":"6","key":"2025012315141362200_R15","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1111\/bcp.13554","article-title":"Meta-analysis of\u00a0trials comparing cefazolin to antistaphylococcal penicillins in\u00a0the treatment of\u00a0methicillin-sensitive Staphylococcus aureus bacteraemia","volume":"84","author":"Rindone","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"3\u20134","key":"2025012315141362200_R16","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1093\/milmed\/usab259","article-title":"Clinical characteristics and\u00a0resistance patterns of\u00a0Pseudomonas aeruginosa isolated from combat casualties","volume":"187","author":"Ford","year":"2022","journal-title":"Mil Med"},{"issue":"Suppl 7","key":"2025012315141362200_R17","doi-asserted-by":"publisher","first-page":"S521","DOI":"10.1093\/cid\/ciz824","article-title":"Epidemiology and\u00a0diagnostics of\u00a0carbapenem resistance in\u00a0gram-negative bacteria","volume":"69","author":"Nordmann","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025012315141362200_R18","article-title":"Avelox (moxifloxacin hydrochloride) prescribing information","author":"Bayer HealthCare"},{"key":"2025012315141362200_R19","article-title":"Flagyl (metronidazole) tablets","author":"Pfizer Inc"},{"key":"2025012315141362200_R20","article-title":"Nuzyra (omadacycline) prescribing information","author":"Paratek Pharmaceuticals"},{"issue":"4","key":"2025012315141362200_R21","doi-asserted-by":"publisher","first-page":"e00047","DOI":"10.1128\/AAC.00047-18","article-title":"In vitro activities of\u00a0omadacycline and\u00a0comparators against anaerobic bacteria","volume":"62","author":"Stapert","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2025012315141362200_R22","article-title":"Paratek JMI Sentry Surveillance Dataset","author":"Paratek Pharmaceuticals","year":"2023"},{"issue":"1","key":"2025012315141362200_R23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12866-020-02019-8","article-title":"Antimicrobial activity of\u00a0omadacycline in\u00a0vitro against bacteria isolated from 2014 to 2017 in\u00a0China, a multi-center study","volume":"20","author":"Xiao","year":"2020","journal-title":"BMC Microbiol"},{"key":"2025012315141362200_R24","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.02546","article-title":"In vitro activity and\u00a0heteroresistance of\u00a0omadacycline against clinical Staphylococcus aureus isolates from china reveal the impact of\u00a0omadacycline susceptibility by branched-chain amino acid transport system II carrier protein, Na\/Pi cotransporter family protein, and\u00a0fibronectin-binding protein","volume":"10","author":"Bai","year":"2019","journal-title":"Front Microbiol"},{"issue":"8","key":"2025012315141362200_R25","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1007\/s10096-020-03877-w","article-title":"In vitro activity of\u00a0omadacycline against pathogens isolated from Mainland China during 2017\u20132018","volume":"39","author":"Dong","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"7","key":"2025012315141362200_R26","doi-asserted-by":"publisher","first-page":"e00624","DOI":"10.1128\/AAC.00624-19","article-title":"In vivo pharmacodynamics of\u00a0omadacycline against Staphylococcus aureus in\u00a0the neutropenic murine thigh infection model","volume":"63","author":"Lepak","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2025012315141362200_R27","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02058-19","article-title":"In vivo pharmacodynamic evaluation of\u00a0omadacycline against Staphylococcus aureus in\u00a0the neutropenic mouse pneumonia model","volume":"64","author":"Lepak","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2025012315141362200_R28","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1089\/mdr.2019.0423","article-title":"Activity of\u00a0omadacycline and\u00a0other tetracyclines against contemporary gram-negative pathogens from New York City hospitals","volume":"27","author":"Iregui","year":"2021","journal-title":"Microb Drug Resist"},{"issue":"3","key":"2025012315141362200_R29","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1093\/jac\/dkaa508","article-title":"In vitro pharmacodynamics of\u00a0omadacycline against Escherichia coli and\u00a0Acinetobacter baumannii","volume":"76","author":"Noel","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"2025012315141362200_R30","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s10096-023-04616-7","article-title":"In vitro activities of\u00a0omadacycline, eravacycline, cefiderocol, apramycin, and\u00a0comparator antibiotics against Acinetobacter baumannii causing bloodstream infections in\u00a0Greece, 2020\u20132021: a multicenter study","volume":"42","author":"Galani","year":"2023","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"6","key":"2025012315141362200_R31","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12060953","article-title":"In vitro activity of\u00a0omadacycline and\u00a0comparator antibiotics against extended-spectrum beta-lactamase-producing Escherichia coli and\u00a0Klebsiella pneumoniae urinary isolates","volume":"12","author":"Stone","year":"2023","journal-title":"Antibiotics (Basel)"},{"issue":"4","key":"2025012315141362200_R32","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics5040032","article-title":"The novel aminomethylcycline omadacycline has high specificity for\u00a0the primary tetracycline-binding site on\u00a0the bacterial ribosome","volume":"5","author":"Heidrich","year":"2016","journal-title":"Antibiotics (Basel)"},{"issue":"10","key":"2025012315141362200_R33","doi-asserted-by":"publisher","first-page":"e00840","DOI":"10.1128\/AAC.00840-20","article-title":"A diverse panel of\u00a0clinical Acinetobacter baumannii for\u00a0research and\u00a0development","volume":"64","author":"Galac","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025012315141362200_R34","article-title":"Preclinical evaluation of\u00a0omadacycline for\u00a0potential as a drug to treat Acinetobacter baumannii and\u00a0Klebsiella pneumoniae infections in\u00a0combat wounds","author":"Raynor"},{"issue":"1","key":"2025012315141362200_R35","doi-asserted-by":"publisher","first-page":"e01784","DOI":"10.1128\/AAC.01784-16","article-title":"Pharmacokinetics, distribution, metabolism, and\u00a0excretion of\u00a0omadacycline following a single intravenous or oral dose of\u00a014c-omadacycline in\u00a0rats","volume":"61","author":"Lin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2025012315141362200_R36","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1093\/jac\/dkac055","article-title":"Omadacycline pharmacokinetics and\u00a0soft-tissue penetration in\u00a0diabetic patients with wound infections and\u00a0healthy volunteers using in\u00a0vivo microdialysis","volume":"77","author":"Gill","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"2025012315141362200_R37","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S1473-3099(19)30275-0","article-title":"Once-daily oral omadacycline versus twice-daily oral linezolid for\u00a0acute bacterial skin and\u00a0skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial","volume":"19","author":"O\u2019Riordan","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"2025012315141362200_R38","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1056\/NEJMoa1800170","article-title":"Omadacycline for\u00a0acute bacterial skin and\u00a0skin-structure infections","volume":"380","author":"O\u2019Riordan","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"2025012315141362200_R39","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1056\/NEJMoa1800201","article-title":"Omadacycline for\u00a0community-acquired bacterial pneumonia","volume":"380","author":"Stets","year":"2019","journal-title":"N Engl J Med"},{"key":"2025012315141362200_R40","article-title":"Treatment of\u00a0wound infection using omadacycline versus linezolid: pooled results from phase 3 randomized, double-blind, multicenter studies (OASIS-1 and\u00a0-2)","author":"Besece"},{"issue":"Suppl 1","key":"2025012315141362200_R41","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1093\/cid\/ciz396","article-title":"Omadacycline for\u00a0acute bacterial skin and\u00a0skin structure infections","volume":"69","author":"Abrahamian","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2025012315141362200_R42","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s40121-021-00587-4","article-title":"Efficacy and\u00a0safety of\u00a0omadacycline versus linezolid in\u00a0acute bacterial skin and\u00a0skin structure infections in\u00a0persons who inject drugs","volume":"11","author":"Moran","year":"2022","journal-title":"Infect Dis Ther"},{"issue":"Suppl 1","key":"2025012315141362200_R43","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1093\/cid\/ciz398","article-title":"An integrated safety summary of\u00a0omadacycline, a novel aminomethylcycline antibiotic","volume":"69","author":"Opal","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"2025012315141362200_R44","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1093\/cid\/ciz309","article-title":"Pharmacokinetics and\u00a0pharmacodynamics of\u00a0oral and\u00a0intravenous omadacycline","volume":"69","author":"Rodvold","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025012315141362200_R45","article-title":"Pew Trusts. Antibiotics currently in\u00a0global clinical development","year":"2022"},{"issue":"3","key":"2025012315141362200_R46","doi-asserted-by":"publisher","first-page":"e01991","DOI":"10.1128\/AAC.01991-21","article-title":"Analysis of\u00a0the clinical pipeline of\u00a0treatments for\u00a0drug-resistant bacterial infections: despite progress, more action is needed","volume":"66","author":"Butler","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2025012315141362200_R47","article-title":"Eravacycline multi-discipline review","author":"Center for Drug Evaluation and Research"},{"issue":"1","key":"2025012315141362200_R48","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1128\/AAC.49.1.220-229.2005","article-title":"Pharmacokinetics of\u00a0tigecycline after single and\u00a0multiple doses in\u00a0healthy subjects","volume":"49","author":"Muralidharan","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"2025012315141362200_R49","doi-asserted-by":"publisher","first-page":"e01135","DOI":"10.1128\/AAC.01135-17","article-title":"Comparison of\u00a0omadacycline and\u00a0tigecycline pharmacokinetics in\u00a0the plasma, epithelial lining fluid, and\u00a0alveolar cells of\u00a0healthy adult subjects","volume":"61","author":"Gotfried","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"18","key":"2025012315141362200_R50","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1001\/archinte.158.18.1993","article-title":"Antimicrobial photosensitive reactions","volume":"158","author":"Vassileva","year":"1998","journal-title":"Arch Intern Med"},{"key":"2025012315141362200_R51","article-title":"Tygacil (tigecycline) prescribing information","author":"Pfizer Inc"},{"issue":"9","key":"2025012315141362200_R52","doi-asserted-by":"publisher","first-page":"e2607","DOI":"10.1093\/cid\/ciaa860","article-title":"Concordance of\u00a0early and\u00a0late end points for\u00a0community-acquired bacterial pneumonia trials","volume":"73","author":"Bart","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2025012315141362200_R53","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-021-01472-z","article-title":"Lefamulin efficacy and\u00a0safety in\u00a0a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and\u00a0common clinical comorbidities","volume":"21","author":"File","year":"2021","journal-title":"BMC Pulm Med"},{"issue":"2","key":"2025012315141362200_R54","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1177\/10600280221089007","article-title":"Omadacycline and\u00a0Clostridioides difficile: a systematic review of\u00a0preclinical and\u00a0clinical evidence","volume":"57","author":"Garey","year":"2023","journal-title":"Ann Pharmacother"},{"issue":"4","key":"2025012315141362200_R55","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1093\/cid\/cix833","article-title":"Low risk of\u00a0primary Clostridium difficile infection with tetracyclines: a systematic review and\u00a0metaanalysis","volume":"66","author":"Tariq","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2025012315141362200_R56","doi-asserted-by":"publisher","first-page":"53","DOI":"10.55460\/ZRIK-EOE3","article-title":"Prehospital administration of\u00a0antibiotic prophylaxis for\u00a0open combat wounds in\u00a0Afghanistan: 2013\u20132014","volume":"18","author":"Schauer","year":"2018","journal-title":"J Spec Oper Med"},{"issue":"3","key":"2025012315141362200_R57","doi-asserted-by":"publisher","first-page":"76","DOI":"10.55460\/X4E8-NNXE","article-title":"Prehospital combat wound medication pack administration in\u00a0Iraq and\u00a0Afghanistan: a department of\u00a0defense trauma registry analysis","volume":"20","author":"Schauer","year":"2020","journal-title":"J Spec Oper Med"},{"issue":"1","key":"2025012315141362200_R58","doi-asserted-by":"publisher","first-page":"61","DOI":"10.55460\/FUHO-CU87","article-title":"An inventory of\u00a0the combat medics\u2019 aid bag","volume":"20","author":"Schauer","year":"2020","journal-title":"J Spec Oper Med"},{"key":"2025012315141362200_R59","article-title":"Extreme temperature study for\u00a0omadacycline tablets and\u00a0intravenous solution","author":"Bower"},{"key":"2025012315141362200_R60","article-title":"Cefazolin prescribing information","author":"Baxter Healthcare Corporation"},{"issue":"3 Suppl 2","key":"2025012315141362200_R61","doi-asserted-by":"publisher","first-page":"S163","DOI":"10.1097\/TA.0000000000000191","article-title":"Modified augmented renal clearance score predicts rapid piperacillin and\u00a0tazobactam clearance in\u00a0critically ill surgery and\u00a0trauma patients","volume":"77","author":"Akers","year":"2014","journal-title":"J Trauma Acute Care Surg"},{"key":"2025012315141362200_R62","article-title":"In vitro activity of\u00a0omadacycline (OMC) against biothreat bacteria","author":"Draper"},{"issue":"5","key":"2025012315141362200_R63","doi-asserted-by":"publisher","first-page":"e02434","DOI":"10.1128\/AAC.02434-16","article-title":"In vitro and\u00a0in vivo activity of\u00a0omadacycline against two biothreat pathogens, Bacillus anthracis and\u00a0Yersinia pestis","volume":"61","author":"Steenbergen","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025012315141362200_R64","volume-title":"Presented at ASM Microbe. Washington DC, USA","author":"Suchland"},{"issue":"6","key":"2025012315141362200_R65","doi-asserted-by":"publisher","first-page":"e03654","DOI":"10.1128\/spectrum.03654-22","article-title":"Omadacycline is highly active in\u00a0vitro against Mycoplasma genitalium","volume":"10","author":"Waites","year":"2022","journal-title":"Microbiol Spectr"},{"issue":"8","key":"2025012315141362200_R66","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.00665-21","article-title":"In vitro susceptibility of\u00a0rickettsia species to eravacycline, omadacycline, and\u00a0tigecycline","volume":"65","author":"Quade","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"2025012315141362200_R67","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1038\/s41564-019-0445-2","article-title":"Emergence of\u00a0plasmid-mediated high-level tigecycline resistance genes in\u00a0animals and\u00a0humans","volume":"4","author":"He","year":"2019","journal-title":"Nat Microbiol"},{"issue":"1","key":"2025012315141362200_R68","doi-asserted-by":"publisher","first-page":"e01326","DOI":"10.1128\/AAC.01326-19","article-title":"Novel plasmid-mediated tet(x5) gene conferring resistance to tigecycline, eravacycline, and\u00a0omadacycline in\u00a0a clinical Acinetobacter baumannii isolate","volume":"64","author":"Wang","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"2025012315141362200_R69","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1038\/s41564-019-0496-4","article-title":"Plasmid-encoded tet(X) genes that confer high-level tigecycline resistance in\u00a0Escherichia coli","volume":"4","author":"Sun","year":"2019","journal-title":"Nat Microbiol"}],"container-title":["Military Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/milmed\/article-pdf\/189\/5-6\/e1353\/57825447\/usad417.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/milmed\/article-pdf\/189\/5-6\/e1353\/57825447\/usad417.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T15:15:24Z","timestamp":1737645324000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/milmed\/article\/189\/5-6\/e1353\/7420206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,31]]},"references-count":69,"journal-issue":{"issue":"5-6","published-online":{"date-parts":[[2023,10,31]]},"published-print":{"date-parts":[[2024,5,18]]}},"URL":"https:\/\/doi.org\/10.1093\/milmed\/usad417","relation":{},"ISSN":["0026-4075","1930-613X"],"issn-type":[{"value":"0026-4075","type":"print"},{"value":"1930-613X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5,1]]},"published":{"date-parts":[[2023,10,31]]}}}